Predictors of relapses in patients with multiple sclerosis treated with disease-modifying drugs

被引：0
|
作者：
Steinman, L.
Obi-Tabot, E.
Wang, H.
Guilhaume, C.
Sondhi, M.
机构：
[1] Stanford Univ, Sch Med, Stanford, CA 94305 USA
[2] Sanofi Aventis R&D, Bridgewater, MA USA
[3] Sanofi Aventis R&D, Massy, France
来源：
MULTIPLE SCLEROSIS JOURNAL | 2011年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P921
引用
收藏
页码：S413 / S413
页数：1
相关论文
共 50 条
  • [41] Development and validation of a claims-based measure as an indicator for disease status in patients with multiple sclerosis treated with disease-modifying drugs
    Michael Munsell
    Molly Frean
    Joseph Menzin
    Amy L. Phillips
    BMC Neurology, 17
  • [42] Association of oral disease-modifying agents and their adherence trajectories with annual relapses in multiple sclerosis
    Earla, Jagadeswara Rao
    Li, Jieni
    Hutton, George J.
    Bentley, John P.
    Aparasu, Rajender R.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 85
  • [43] Baseline predictors of persistence to first disease-modifying treatment in multiple sclerosis
    Zettl, U. K.
    Schreiber, H.
    Bauer-Steinhusen, U.
    Glaser, T.
    Hechenbichler, K.
    Hecker, M.
    ACTA NEUROLOGICA SCANDINAVICA, 2017, 136 (02): : 116 - 121
  • [44] Psychosocial predictors of patient adherence to disease-modifying therapies for multiple sclerosis
    Alosaimi, Fahad D.
    AlMulhem, Alaa
    AlShalan, Hanan
    Alqazlan, Mohammad
    Aldaif, Abdulgader
    Kowgier, Matthew
    Balasundaram, Janooshsheya
    Sockalingam, Sanjeev
    PATIENT PREFERENCE AND ADHERENCE, 2017, 11 : 513 - 518
  • [45] Assessment and management of infectious risk in multiple sclerosis patients treated with disease-modifying therapies
    Zingaropoli, Maria Antonella
    Pasculli, Patrizia
    Iannetta, Marco
    Perri, Valentina
    Tartaglia, Matteo
    Crisafulli, Sebastiano Giuseppe
    Merluzzo, Chiara
    Baione, Viola
    Mazzocchi, Lorenzo
    Taglietti, Ambra
    Pauri, Flavia
    Frontoni, Marco
    Altieri, Marta
    Gaeta, Aurelia
    Antonelli, Guido
    Conte, Antonella
    Mastroianni, Claudio
    Ciardi, Maria Rosa
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 429
  • [46] Retrospective data collection of multiple sclerosis patients treated with disease-modifying therapies in Latvia
    Metra, M.
    Elsone, L.
    Murzina, M.
    Kalnina, J.
    Paegle, A.
    JOURNAL OF NEUROLOGY, 2010, 257 : S147 - S147
  • [47] Treatment patterns of multiple sclerosis patients treated with disease-modifying therapies in Puerto Rico
    Chia, J.
    Nunez, M.
    Hernandez, H.
    Jimenez, G.
    Ong, A.
    Hashemi, L.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 764 - 764
  • [48] Use of disease-modifying drugs in multiple sclerosis: A population based study
    Noyes, K.
    Bajorska, A.
    Schwid, S.
    Holloway, R.
    Dick, A.
    VALUE IN HEALTH, 2008, 11 (03) : A150 - A151
  • [49] Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study
    Wijnands, Jose Maria Andreas
    Zhu, Feng
    Kingwell, Elaine
    Fisk, John David
    Evans, Charity
    Marrie, Ruth Ann
    Zhao, Yinshan
    Tremlett, Helen
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2018, 89 (10): : 1050 - 1056
  • [50] Pregnancy exposure to disease-modifying drugs in multiple sclerosis: a prospective study
    Pablo Cuello, Juan
    Salgado Camara, Paula
    Garcia Dominguez, Jose Manuel
    Lozano Ros, Alberto
    Mas Serrano, Miguel
    Martinez Gines, Maria Luisa
    MEDICINA CLINICA, 2020, 154 (06): : 214 - 217
12345